PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran ...

The study was a randomized, placebo-controlled comparison of the effects of daily treatment with fenofibrate 160 mg, ezetimibe-simvastatin 10/20 mg, ezetimibe-simvastatin 10/20 mg plus fenofibrate 160 ...

Please provide your email address to receive an email when new articles are posted on . Two small interfering RNA therapies lowered triglyceride levels in patients with mixed hyperlipidemia at 24 ...

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - ARO-DIMER-PA is the first clinical ...

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals, known to be at ...

NEW ORLEANS, November 8, 2004 – Results from a new study showed that coadministration of ZETIA® (ezetimibe) and fenofibrate significantly reduced LDL ("bad") cholesterol (LDL-C), non-high density ...

Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of-function carriers have lower levels of ...

Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia – elevations of triglycerides and cholesterol ...

Arrowhead Pharmaceuticals, Inc. (ARWR) announced an update on their ongoing clinical study. This Phase 1/2a study, officially titled “Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple ...